Literature DB >> 17934338

Expression of CCR2A, an isoform of MCP-1 receptor, is increased by MCP-1, CD40 ligand and TGF-beta in fibroblast like synoviocytes of patients with RA.

Mi-La Cho1, Bo-Young Yoon, Ji-Hyeon Ju, Young Ok Jung, Joo-Yeon Jhun, Mi-Kyung Park, Sung-Hwan Park, Chul-Soo Cho, Ho-Youn Kim.   

Abstract

Cytokine and chemokine receptors play a key role in inflammation caused by rheumatoid arthritis (RA). Two isoforms of human CC chemokine receptor R2 (CCR2), the receptor of monocyte chemoattractant protein 1 (MCP-1), have been identified but their relative expression in fibroblast-like synoviocytes (FLS) and their contribution to inflammatory responses mediated by MCP-1 or inflammatory cytokines in patients with RA remain uncertain. We examined the pattern of expression of two CCR2 isoforms upon stimulation by proinflammatory cytokines and CD40 ligation. FLS were prepared from the synovial tissues of RA patients and cultured in the presence of MCP-1, soluble CD40 ligand (sCD40L), TGF-beta, IL-1beta, IL-18, IL-15, and LPS. CCR2A and CCR2B expression was examined by immunohistochemistry, RT-PCR and western blot analysis. IL-15, TNF-alpha and MCP-1 production was determined by ELISA. Immunohistochemistry showed that CCR2A is highly expressed in RA synovium compared with OA synovium. Transcripts of both CCR2A and CCR2B were detected in FLS. Exogenous MCP-1, CD40L, TGF-beta, and IL-15 significantly increased the expression of CCR2A but not CCR2B. Exposure of FLS to sCD40L caused strong upregulation of CCR2A but not of CCR2B protein expression. MCP-1 increased the proliferation of FLS and the production of IL-15, TNF-alpha, and IL-18. Because CCR2A is the main target of regulation by cytokines and CD40 ligation, the relatively higher expression of CCR2A on the cell surface suggests that this isoform of MCP-1 receptor functions as the principal mediator of inflammatory signals in RA FLS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934338     DOI: 10.1038/emm.2007.55

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  9 in total

1.  Promoter -2518 single nucleotide polymorphism of monocyte chemoattractant protein-1 is associated with clinical severity in Behçet's disease.

Authors:  Seong-Kyu Kim; Won-Cheoul Jang; Young-Chang Ahn; Sang-Hyun Lee; Shin-Seok Lee; Jin-Wuk Hur
Journal:  Inflamm Res       Date:  2012-04-03       Impact factor: 4.575

Review 2.  Monocyte chemoattractant protein-1 and the blood-brain barrier.

Authors:  Yao Yao; Stella E Tsirka
Journal:  Cell Mol Life Sci       Date:  2013-09-20       Impact factor: 9.261

3.  The protective effect of MCP-1 -2518 A>G promoter polymorphism in Turkish chronic renal failure patients requiring long-term hemodialysis.

Authors:  Binnur Bagci; Gokhan Bagci; Ferhan Candan; Ozturk Ozdemir; Ilhan Sezgin
Journal:  Int Urol Nephrol       Date:  2015-02-06       Impact factor: 2.370

Review 4.  Monocyte chemoattractant protein-1 (MCP-1): an overview.

Authors:  Satish L Deshmane; Sergey Kremlev; Shohreh Amini; Bassel E Sawaya
Journal:  J Interferon Cytokine Res       Date:  2009-06       Impact factor: 2.607

Review 5.  Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?

Authors:  Liyang Fei; Xiaochen Ren; Haijia Yu; Yifan Zhan
Journal:  Front Immunol       Date:  2021-11-03       Impact factor: 7.561

6.  Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA rat model.

Authors:  Hyun Sik Na; Seon-Yeong Lee; Dong Hwan Lee; Jin Seok Woo; Si-Young Choi; Keun-Hyung Cho; Seon Ae Kim; Eun Jeong Go; A Ram Lee; Jeong-Won Choi; Seok Jung Kim; Mi-La Cho
Journal:  J Transl Med       Date:  2022-09-23       Impact factor: 8.440

Review 7.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

8.  Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations.

Authors:  Yousof Taghavi; Gholamhossein Hassanshahi; Nicholas G Kounis; Ioanna Koniari; Hossein Khorramdelazad
Journal:  J Cell Commun Signal       Date:  2019-01-03       Impact factor: 5.908

9.  Positive and negative cooperativity of TNF and Interferon-γ in regulating synovial fibroblast function and B cell survival in fibroblast/B cell co-cultures.

Authors:  Torsten Lowin; Tareq M Anssar; Marina Bäuml; Tim Classen; Matthias Schneider; Georg Pongratz
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.